Van Gerwen F, Van der Korst J K, Gribnau F W
Ann Rheum Dis. 1978 Feb;37(1):85-8. doi: 10.1136/ard.37.1.85.
In a double-blind double-placebo crossover study naproxen (500-750 mg daily) was found to be equivalent to phenylbutazone (400-600 mg daily) in the control of disease activity in 20 patients suffering from ankylosing spondylitis during a two times 5-week trial period. No serious side effects were observed during the trial period. Gastric complaints occurred twice as often under phenylbutazone as under naproxen.
在一项双盲双安慰剂交叉研究中，发现在为期两周、每周5周的试验期内，萘普生（每日500 - 750毫克）在控制20例强直性脊柱炎患者的疾病活动方面与保泰松（每日400 - 600毫克）等效。试验期间未观察到严重副作用。保泰松组出现胃部不适的频率是萘普生组的两倍。
